Anne Younger

A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors

E. Gabriela Chiorean, Patricia LoRusso, Robert Matthew Strother et al. · Clinical Cancer Research · 2015 · 147 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

Daruka Mahadevan, E. Gabriela Chiorean, Wayne B. Harris et al. · European Journal of Cancer · 2012 · 134 citations

Medicine, Oncology, Pharmacology +11

Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors

E. Gabriela Chiorean, Daruka Mahadevan, Wayne B. Harris et al. · Journal of Clinical Oncology · 2009 · 26 citations

Medicine, Oncology, Pharmacology +17

Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.

Amikar Sehdev, Harvey Cramer, Ashley Ibrahim et al. · PubMed · 2016 · 22 citations

Medicine, Molecular Genetics, Oncology +17

Phase I study of REGN421 (R)/SAR153192, a fully-human delta-like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors.

Antonio Jimeno, Patricia LoRusso, Robert Matthew Strother et al. · Journal of Clinical Oncology · 2013 · 15 citations

Medicine, Oncology, Pharmacology +17